Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers

Prochazka,Pavel; Hrabeta,Jan; Vicha,Ales; Cipro,Simon; Stejskalova,Eva; Musil,Zdenek; Vodicka,Pavel; Eckschlager,Tomas

doi:10.3892/or.2013.2383

Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers

Authors:
- Pavel Prochazka
- Jan Hrabeta
- Ales Vicha
- Simon Cipro
- Eva Stejskalova
- Zdenek Musil
- Pavel Vodicka
- Tomas Eckschlager
View Affiliations

Affiliations: Department of Paediatric Hematology and Oncology, Second Medical School, Charles University in Prague and University Hospital Motol, 15006 Prague, Czech Republic, Institute of Biology and Medical Genetics, Charles University in Prague, First Faculty of Medicine and General Teaching Hospital, 12108, Prague 2, Czech Republic, Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, 14200 Prague 4, Czech Republic
Published online on: April 4, 2013 https://doi.org/10.3892/or.2013.2383
Pages: 2415-2421

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma is a tumor accounting for approximately 10% of all childhood malignancies and 50% of all childhood cancer-related deaths. MYCN gene copy number variation represents the most important prognostic factor in neuroblastoma. Prognostic significance of MYCN gene expression is more complicated and may depend on other factors such as MYCN gene copy number status. In the present study, we assessed MYCN gene expression using real-time RT-PCR following cisplatin treatment in three human neuroblastoma cell lines (UKF-NB-3, UKF-NB-4 and SK-N-AS) and their cisplatin-resistant counterparts. We also examined MYCN gene status and copy number (gain and amplification) variations using interphase and metaphase fluorescent in situ hybridization (FISH) and multiplex ligation-dependent probe amplification (MLPA). Only cisplatin-sensitive UKF-NB-4 cells exhibited decreased MYCN expression following treatment with cisplatin. Other sensitive neuroblastoma cells did not exhibit a change in MYCN expression. In contrast, cisplatin-resistant UKF-NB-4 and SK-N-AS cells exhibited increased MYCN expression irrespective of the number of MYCN copies or concentration of cisplatin in the medium. In MYCN-amplified neuroblastoma cells we did not observe any significant change in the number of MYCN copies after cisplatin treatment, whereas MYCN-non-amplified SK-N-AS cells revealed during cisplatin treatment an increased number of MYCN gene copies caused by 2p gain in the majority of cells by FISH. We postulated that cisplatin treatment does not result directly in altered transcription of MYCN. A functional change in MYCN mRNA levels and increased MYCN expression in cisplatin-resistant neuroblastoma cells do not have a clear relationship to MYCN copy numbers. These findings may further contribute to the understanding of cisplatin chemotherapy in connection with MYCN expression, and the possible copy number variations in MYCN neuroblastoma cells may be of importance since targeting of MYCN is being tested as neuroblastoma therapy.

View Figures

View References

1	Schwab M: MYCN in neuronal tumours. Cancer Lett. 204:179–187. 2004. View Article : Google Scholar
2	Kyo Y, Tanaka T, Hayashi K, et al: Identification of therapy-sensitive and therapy-resistant neuroblastoma subtypes in stages III, IVs and IV. Cancer Lett. 306:27–33. 2011. View Article : Google Scholar : PubMed/NCBI
3	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
4	Westermark UK, Wilhelm M, Frenzel A and Henriksson MA: The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 21:256–266. 2011.
5	Souzaki R, Tajiri T, Teshiba R, et al: The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma. Pediatr Surg Int. 27:231–236. 2011. View Article : Google Scholar : PubMed/NCBI
6	Ambros PF, Ambros IM, Brodeur GM, et al: International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 100:1471–1482. 2009. View Article : Google Scholar : PubMed/NCBI
7	Prochazka P, Hrabeta J, Vicha A and Eckschlager T: Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine. Cancer Genet Cytogenet. 196:96–104. 2010. View Article : Google Scholar
8	Baumann Kubetzko FB, Di Paolo C, Maag C, et al: The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis. 25:1839–1846. 2004.PubMed/NCBI
9	Bian X, Giordano TD, Lin HJ, Solomon G, Castle VP and Opipari AW Jr: Chemotherapy-induced apoptosis of S-type neuroblastoma cells requires caspase-9 and is augmented by CD95/Fas stimulation. J Biol Chem. 279:4663–4669. 2004. View Article : Google Scholar : PubMed/NCBI
10	Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
11	de Cremoux P, Jourdan-Da-Silva N, Couturier J, et al: Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer. 48:311–317. 2007.
12	Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003. View Article : Google Scholar
13	Tang XX, Zhao H, Kung B, et al: The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res. 66:2826–2833. 2006.
14	Lutz W and Schwab M: In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells. Oncogene. 15:303–315. 1997. View Article : Google Scholar : PubMed/NCBI
15	Westermann F, Muth D, Benner A, et al: Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 9:R1502008. View Article : Google Scholar : PubMed/NCBI
16	Fulda S, Lutz W, Schwab M and Debatin KM: MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene. 18:1479–1486. 1999.
17	Porro A, Haber M, Diolaiti D, et al: Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells. J Biol Chem. 285:19532–19543. 2010. View Article : Google Scholar
18	Bell E, Chen L, Liu T, Marshall GM, Lunec J and Tweddle DA: MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 293:144–157. 2010. View Article : Google Scholar : PubMed/NCBI
19	Albihn A, Johnsen JI and Henriksson MA: MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 107:163–224. 2010. View Article : Google Scholar : PubMed/NCBI
20	Gustafson WC and Weiss WA: Myc proteins as therapeutic targets. Oncogene. 29:1249–1259. 2010. View Article : Google Scholar : PubMed/NCBI
21	Prochazka P, Libra A, Zemanova Z, et al: Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells. Cancer Sci. 103:334–341. 2012. View Article : Google Scholar : PubMed/NCBI
22	Kotchetkov R, Cinatl J, Blaheta R, et al: Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer. 104:36–43. 2003. View Article : Google Scholar : PubMed/NCBI
23	Poljakova J, Eckschlager T, Hrabeta J, et al: The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol. 77:1466–1479. 2009. View Article : Google Scholar : PubMed/NCBI
24	Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
25	Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM and Norris MD: Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 54:5036–5040. 1994.
26	Beiske K, Ambros PF, Burchill SA, Cheung IY and Swerts K: Detecting minimal residual disease in neuroblastoma patients - the present state of the art. Cancer Lett. 228:229–240. 2005. View Article : Google Scholar : PubMed/NCBI
27	Hogarty MD, Norris MD, Davis K, et al: ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res. 68:9735–9745. 2008. View Article : Google Scholar
28	Ambros PF and Ambros IM; SIOP Europe Neuroblastoma Pathology, Biology and Bone Marrow Group. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol. 37:492–504. 2001. View Article : Google Scholar : PubMed/NCBI
29	Valent A, Le Roux G, Barrois M, et al: MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. J Pathol. 198:495–501. 2002. View Article : Google Scholar : PubMed/NCBI
30	Jeison M, Ash S, Halevy-Berko G, et al: 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics. Am J Pathol. 176:2616–2625. 2010.PubMed/NCBI
31	Spitz R, Hero B, Skowron M, Ernestus K and Berthold F: MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Eur J Cancer. 40:2753–2759. 2004. View Article : Google Scholar
32	Cohen N, Betts DR, Rechavi G, Amariglio N and Trakhtenbrot L: Clonal expansion and not cell interconversion is the basis for the neuroblast and nonneuronal types of the SK-N-SH neuroblastoma cell line. Cancer Genet Cytogenet. 143:80–84. 2003.PubMed/NCBI
33	Ambros IM, Brunner B, Aigner G, et al: A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res. 17:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
34	Chan HS, Gallie BL, DeBoer G, et al: MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res. 3:1699–1706. 1997.
35	Cohn SL, London WB, Huang D, et al: MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol. 18:3604–3613. 2000.PubMed/NCBI
36	Bieche I, Laurendeau I, Tozlu S, et al: Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res. 59:2759–2765. 1999.
37	Smith DR and Goh HS: Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene. Clin Cancer Res. 2:1049–1053. 1996.PubMed/NCBI
38	Paffhausen T, Schwab M and Westermann F: Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett. 250:17–24. 2007.
39	Bedrnicek J, Vicha A, Jarosova M, et al: Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Neoplasma. 52:415–419. 2005.PubMed/NCBI
40	van Noesel MM, Pieters R, Voute PA and Versteeg R: The N-myc paradox: N-myc overexpression in neuroblastomas is associated with sensitivity as well as resistance to apoptosis. Cancer Lett. 197:165–172. 2003.PubMed/NCBI
41	Wasenius VM, Jekunen A, Monni O, et al: Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer. 18:286–291. 1997. View Article : Google Scholar
42	Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S and Fukuzawa M: Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol. 30:1189–1196. 2007.